PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same ...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platform Bria-Pros+ is capable of activating ...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response ...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases ...
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s ...
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. ...
BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning ...
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital ...
Accessibility Tools